We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord

Ticker
MGX

Price
1.45
Stock movement down
-0.03 (-2.03%)
Company name
Metagenomi, Inc. Common Stock
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Market cap
54.42M
Ent value
-
Price/Sales
-
Price/Book
-
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
-
Forward P/E
-
PEG
-
EPS growth
-
1 year return
-65.56%
3 year return
-
5 year return
-
10 year return
-
Last updated: 2025-08-27

iO Charts is a Seeking Alpha partner

DIVIDENDS

MGX does not pay dividends or no data was received

iO Charts is a Seeking Alpha partner

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E-
Price to OCF-
Price to FCF-
Price to EBITDA-
EV to EBITDA-

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales-
Price to Book-
EV to Sales-

iO Charts is a Seeking Alpha partner

FINANCIALS

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open1.49
Daily high1.52
Daily low1.42
Daily Volume496K
All-time high12.25
1y analyst estimate9.50
Beta-
EPS (TTM)-
Dividend per share-
Ex-div date-
Next earnings date12 Nov 2025

Downside potential

Loading...
Downside potential data
MGXS&P500
Current price drop from All-time high-88.16%-3.04%
Highest price drop-89.71%-56.47%
Date of highest drop3 Apr 20259 Mar 2009
Avg drop from high-65.45%-11.04%
Avg time to new high68 days12 days
Max time to new high338 days1805 days

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

COMPANY DETAILS
MGX (Metagenomi, Inc. Common Stock) company logo
Marketcap
54.42M
Marketcap category
Small-cap
Description
Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. Its genome editing toolbox includes nuclease-based genome editing, base editors, RNA-mediated integration, including prime editing, and DNA-mediated integration, such CRISPR-associated transposases. The company has a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop and commercialize investigational medicines using genome editing technologies; and a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited TCR-based therapeutic products exclusively in the field of treatment, prevention, or diagnosis of any human cancer. Metagenomi, Inc. was incorporated in 2016 and is headquartered in Emeryville, California.
Employees
171
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

UNDERSTAND THE BUSINESS
Loading...